logo
New bird flu infections in Nevada dairy cattle signal the virus may be here to stay

New bird flu infections in Nevada dairy cattle signal the virus may be here to stay

CNN06-02-2025
Six dairy herds in Nevada have tested positive for a newer variant of the H5N1 bird flu virus that's been associated with severe infections in humans, according to the Nevada Department of Agriculture.
Scientists say these infections with a different type of virus mark an inflection point in the nation's efforts to contain the virus: It may be here to stay.
The strain is not the same one that has been circulating in other dairy herds throughout the United States, a virus called B3.13. The newer version, D1.1, has previously been detected only in birds and in people who had contact with infected birds.
This is the first time it has been found in dairy cattle, meaning that these cows caught it from wild birds, instead of another infected herd. This is the second known instance of a type of avian flu being introduced into cattle herds by birds and It suggests the virus could be seeding itself into herds through introductions from wild birds, which are ubiquitous.
That could mean the H5N1 infection might become endemic, or continuously circulating, in birds in North America, and that may eventually spell trouble for people, too.
'In my opinion, it is now endemic, and it should be classified as an endemic virus,' said Dr. Louise Moncla, a pathobiologist at the University of Pennsylvania who runs a lab that studies how viruses emerge in human populations and spread.
The US Department of Agriculture currently classifies H5N1 as a foreign animal disease, meaning an infectious disease in animals that is not currently present in the United States. In an October news briefing, Dr. Eric Deeble, deputy undersecretary for marketing and regulatory programs at the USDA, said agriculture officials were still confident that H5N1 could be eliminated in the national herd.
Experts said repeated infections of cattle by wild birds will make that that possibility more remote.
'It's much easier to control virus spread when you're talking about a virus spreading from cow to cow than controlling spread from birds to cows,' said Dr. Scott Hensley, a microbiologist who studies the evolution of flu viruses at the University of Pennsylvania's Perelman School of Medicine.
This isn't the first time the US has had to contend with such a destructive bird flu outbreak.
In 2014, highly pathogenic H5N8 bird flu viruses from Europe arrived in North America, resulting in the destruction of more than 50 million commercially farmed birds. This aggressive culling worked. North America remained free from highly pathogenic bird flu viruses for years.
Moncla thinks this go-round with the virus will be a different story, however. Moncla and her team recently posted a preprint study on how the H5N1 virus was introduced in North America in late 2021 and quickly found its way onto farms. By studying the evolution of the virus, they determined spread into poultry flocks was driven by somewhere between 46 and 113 different introductions of the virus from wild to farmed birds. Now, she says, with the virus spreading in so many different species of mammals and birds, it is likely to be here to stay.
Though all six of the recently infected Nevada herds are located in the same valley, Dr. J.J. Goicoechea, director of the Nevada Department of Agriculture, said that after conversations with the farmers and with his state veterinarian, they believe the infection was introduced separately at each of the dairies by wild birds.
Goicoechea said there doesn't seem to be a lot of movement of people or equipment between the dairies, which have been following strict biosecurity protocols. He said the state is working with the US Department of Agriculture on genetic testing to see if there are changes to the virus that might help them understand its spread.
D1.1 has been associated with two severe infections in people: a teenager in British Columbia who was hospitalized in critical condition last fall but eventually recovered and a senior in Louisiana who died from their infection in January. Farm workers in Washington state have also tested positive for D1.1 after culling infected poultry. Their symptoms were described as milder.
Scientists are studying the D1.1 strain to try to learn more about its capabilities and how it appears to be spreading so aggressively.
'D1.1 was initially found, I believe, in August of 2024 in the Pacific Flyway. It's now in all four flyways, and so we know it's in the environment, but this is the first time it's been documented that D1.1 has been in a dairy cow,' said Goicoechea.
The affected dairies have provided the Nevada Department of Health and Human Services with contact information for workers who are being monitored for signs of infection, and they are being offered personal protective equipment, Goicoechea said.
To date, no humans have tested positive in connection with the infected herds in Nevada.
Notably, the D1.1 infections in cows do not appear to be more severe than B3.13 infections, Goicoechea said. 'We're seeing exactly the same clinical signs,' Goicoechea said. Cows lose their appetite, and their milk production drops. Most recover with veterinary care. 'It's very, very similar signs to what we've seen for really the last year, since this started in Texas and Kansas,' he said.
The newly infected Nevada herds were detected on January 31 through a US Department of Agriculture program that is testing milk in large silos across the US.
'Lots of different bulk tanks from different farms can come into one silo. And then they trace it back,' said Dr. Seema Lakdawala, a microbiologist and immunologist at Emory University who has been studying how the H5N1 virus is infecting cows.
Lakdawala says the finding raises critical questions about how dairy cattle are being exposed and whether it's possible to contain the H5N1 outbreak, which is rapidly spreading among animals and birds, though health officials say most people are still at low risk from the virus.
Since March 2024, H5N1 avian influenza has been detected in 957 herds in 16 states, according to the USDA. There have been 67 infections confirmed in humans in the US, nearly all of them farm workers who had contact with infected animals, according to the CDC. That number is believed to represent a fraction of the true number of human infections, however. A CDC study testing the blood of exposed farmworkers found 7% of them had developed antibodies against the virus, suggested they had previously been infected.
Get CNN Health's weekly newsletter
Sign up here to get The Results Are In with Dr. Sanjay Gupta every Friday from the CNN Health team. A recent study published in the New England Journal of Medicine on the first 46 documented human infections in the US determined that all had mild symptoms that began with red, inflamed eyes and a fever. None of these first patients who became ill after contact with sick animals was hospitalized.
Researchers don't know why most human infections with avian flu in the US — which have primarily been with the B3.13 strain — have been mild. One reason may be that H5N1 is clumsy at infecting people. It prefers to latch onto a certain configuration of a sugar called a sialic acid that's plentiful on the cells of birds. Humans have these kinds of sialic acids, too, but they're relatively rare on cells in the human respiratory tract, which is where flu viruses need to land to make us really ill.
Scientists agree that the more H5N1 spreads, the more likely it is to change in ways that could help it get better at infecting people.
'I would say everybody's really interested in D1.1 right now, because it seemingly came out of nowhere and then caused two very severe human infections,' Moncla said. 'So people are quite worried about it.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Novavax's H5N1 Vaccine Candidate Demonstrates Immunogenicity in Preclinical Study
Novavax's H5N1 Vaccine Candidate Demonstrates Immunogenicity in Preclinical Study

Yahoo

time4 hours ago

  • Yahoo

Novavax's H5N1 Vaccine Candidate Demonstrates Immunogenicity in Preclinical Study

Peer-reviewed data shows Novavax's H5N1 vaccine candidate demonstrated immunogenicity against currently circulating variants following either single or two-dose administration Potential for single intranasal or intramuscular dose could differentiate Novavax's vaccine as part of pandemic emergency preparedness efforts GAITHERSBURG, Md., July 24, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced preclinical data demonstrating that Novavax's H5N1 avian pandemic influenza vaccine candidate, leveraging Novavax's recombinant, protein-based nanoparticle technology and Matrix-M® adjuvant, induced robust immune responses by either single or two-dose intranasal (IN) or intramuscular (IM) administration in nonhuman primates. Results were published in Nature Communications. "These preclinical results underscore the promise and potential of our pandemic influenza program as well as the strength of our technology platform and our ability to deliver against our corporate growth strategy," said Ruxandra Draghia-Akli, MD, PhD, Executive Vice President and Head of Research and Development, Novavax. "Our R&D pipeline focuses on delivering assets ready for partnership and prioritizing areas of unmet medical need, including vaccines for avian pandemic influenza, where we see clear potential advantages for our technology compared with other vaccines that are licensed or in development." Results showed that a single dose administered by either IN or IM routes induced neutralizing antibody responses (IN: 1:54; IM: 1:1,160), at or above the 1:40 titer generally considered to be a protective antibody response. The data showed even higher levels of immunity after two doses. These data suggest that even a single IN dose has the potential to provide protective immunity in individuals previously exposed to seasonal influenza either by vaccination or infection. Further, data showed Novavax's H5N1 vaccine candidate elicited broad antibody responses, suggesting the potential to protect against forward-drift variants from currently circulating strains of the H5N1 virus. H5N1, a highly pathogenic and dynamic avian pandemic influenza virus, is of concern due to its potential to mutate into a strain adapted for sustained human-to-human transmission. To date, there have been 70 confirmed total reported human cases in the U.S., and one death associated with H5N1 avian pandemic influenza infection.1 As of July 2025, no reported cases in the U.S. have been proven to result from human-to-human transmission. As part of its corporate growth strategy, Novavax is making targeted investments in early-stage development programs to create value. Novavax intends to pursue funding, partnership and licensing opportunities for its H5N1 vaccine candidate. About Novavax Novavax, Inc. (Nasdaq: NVAX) tackles some of the world's most pressing health challenges with its scientific expertise in vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M adjuvant. The Company's growth strategy seeks to optimize its existing partnerships and expand access to its proven technology platform via research and development (R&D) innovation, organic portfolio expansion in infectious disease and beyond, and forging new partnerships and collaborations with other companies. Please visit and LinkedIn for more information. Forward-Looking Statements Statements herein relating to the future of Novavax, its operating plans and prospects, its partnerships, and the potential for a single intranasal or intramuscular dose differentiating Novavax's H5N1 vaccine, are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, challenges pursuing additional partnership opportunities; challenges satisfying, alone or together with partners, various safety, efficacy, and product characterization requirements, including those related to process qualification, assay validation and stability testing, necessary to satisfy applicable regulatory authorities; challenges or delays in conducting clinical trials or studies for its product candidates; challenges or delays in obtaining regulatory authorization for its product candidates, including for future COVID-19 variant strain changes, its CIC vaccine candidate, its stand-alone influenza vaccine candidate or other product candidates; manufacturing, distribution or export delays or challenges; Novavax's substantial dependence on Serum Institute of India Pvt. Ltd. and Serum Life Sciences Limited for co-formulation and filling Novavax's COVID-19 vaccine and the impact of any delays or disruptions in their operations; difficulty obtaining scarce raw materials and supplies including for its proprietary adjuvant; resource constraints, including human capital and manufacturing capacity; constraints on Novavax's ability to pursue planned regulatory pathways, alone or with partners; challenges in implementing its global restructuring and cost reduction plan; challenges in obtaining commercial adoption and market acceptance of its updated COVID-19 vaccine or any COVID-19 variant strain containing formulation, or for its CIC vaccine candidate and stand-alone influenza vaccine candidate or other product candidates; challenges meeting contractual requirements under agreements with multiple commercial, governmental, and other entities, including requirements to deliver doses that may require Novavax to refund portions of upfront and other payments previously received or result in reduced future payments pursuant to such agreements and challenges in amending or terminating such agreements; challenges related to the seasonality of vaccinations against COVID-19; challenges related to the demand for vaccinations against COVID-19 or influenza; challenges in identifying and successfully pursuing innovation expansion opportunities; Novavax's expectations as to expenses and cash needs may prove not to be correct for reasons such as changes in plans or actual events being different than its assumptions; and those other risk factors identified in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Novavax's Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent Quarterly Reports on Form 10-Q, as filed with the Securities and Exchange Commission (SEC). We caution investors not to place considerable reliance on forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at and for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties. Contacts: Investors Luis Sanay, CFA 240-268-2022 ir@ Media Giovanna Chandler (844) 264-8571 media@ References U.S. Centers for Disease Control and Prevention. H5 Bird Flu: Current Situation. 2025. Available at: View original content to download multimedia: SOURCE Novavax, Inc.

Microbix Exhibiting & Presenting at ADLM
Microbix Exhibiting & Presenting at ADLM

Hamilton Spectator

time5 hours ago

  • Hamilton Spectator

Microbix Exhibiting & Presenting at ADLM

MISSISSAUGA, Ontario, July 24, 2025 (GLOBE NEWSWIRE) — Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it will be attending, exhibiting, and presenting at the Association for Diagnostic & Laboratory Medicine ('ADLM') conference taking place in Chicago, Illinois July 28 to 31, 2025. At ADLM, Microbix will exhibit alongside leading firms that provide tests to diagnose and direct treatment of many infectious and other diseases. Microbix will thereby showcase its ever-growing portfolio of quality assessment products ('QAPs™') that help ensure the accuracy of antigen and molecular (i.e., 'PCR' or 'NAAT') tests and their workflows. Microbix will also be meeting with many current and prospective clients to determine how best to support their quality management system needs. Also at ADLM, Microbix will present results of a pilot External Quality Assessment (EQA) program enabled by Microbix QAPs. Its poster is titled 'Quality Control Rapid Response in Pre-Pandemic Preparedness Showcasing a Synthetic H5N1 Genetic Template.' which reviews the performance of novel QAPs for answering the critical question of whether pre-existing molecular tests for Influenza A can accurately detect the emerging H5N1 (Bird Flu) pandemic strain. A Microbix customer and collaborator, American Proficiency Institute ('API'), is presenting a related poster titled 'Evaluation of NAAT Recovery of Highly Pathogenic Avian Influenza A (H5N1) Clade 2.3.4.4b from Novel Proficiency Samples.' After each poster is presented at ADLM, they will be made available at . The two posters detail the results of work first announced on January 13, 2025, whereby Microbix and API disclosed the creation of QAPs and a pilot proficiency testing program for evaluating the performance of Flu tests in detecting H5N1. As widely reported in the media, H5N1 Flu is a novel variant for which the human population does not have established immunity. Accordingly, H5N1 Flu has pandemic potential, with it having thus far caused severe disease or death in approximately 50% of those persons infected. Microbix gratefully acknowledges the vital role of API in helping to conduct this societally important work. Amer Alagic, Microbix's Director of R&D and lead author of its poster commented, 'Working alongside API, our team is privileged to help answer vital questions concerning the accuracy and usefulness of currently available Flu tests for detecting H5N1. Microbix's novel H5N1 QAPs were created by our team to ensure full genetic coverage of a potential pandemic strain and were made safely under Microbix IP and with cutting-edge synthetic biology techniques. H5N1 QAPs are fully-characterized, accurately-quantified, and are available in liquid and FLOQSwab formats to support both lab-based and point-of-care assays. These Microbix capabilities can be rapidly deployed in response to any emerging pandemic.' Purchase enquiries for these or other Microbix QAPs can be e-mailed to . About Microbix Biosystems Inc. Microbix Biosystems Inc. creates proprietary biological products for human health, with over 120 skilled employees and revenues targeting C$ 2.0 million or more per month. It enables the worldwide commercialization of diagnostic assays by making a wide range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs™) that support clinical lab proficiency-testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its antigens drive the antibody tests of approximately 100 diagnostics makers, while QAPs are sold to clinical lab accreditation organizations, diagnostics companies, and clinical labs. Microbix QAPs are now available in over 30 countries, supported by a network of international distributors. Microbix is ISO 9001 & 13485 accredited, U.S. FDA registered, Australian TGA registered, Health Canada establishment licensed, and provides IVDR-compliant CE marked products. Microbix also applies its biological expertise and infrastructure to develop other proprietary products and technologies, most notably Kinlytic® urokinase, a biologic thrombolytic drug used to treat blood clots, and reagents or media to support molecular diagnostic testing (e.g., its DxTM™ for patient-sample collection). Microbix is traded on the TSX and OTCQX, and headquartered in Mississauga, Ontario, Canada. Forward-Looking Information This news release includes 'forward-looking information,' as such term is defined in applicable securities laws. Forward-looking information includes, without limitation, discussion of API, the pilot proficiency testing program, the H5N1 QAPs, or their relevance, Microbix's or others' products or services, business and business results, goals or outlook, risks associated with financial results and stability, development projects such as those referenced in its presentations, regulatory compliance and approvals, access and sales to foreign jurisdictions, engineering and construction, production (including control over costs, quality, quantity or timeliness of delivery), currency exchange rates, maintaining adequate working capital or raising new capital on acceptable terms or at all, and other similar statements about anticipated future events, conditions or results that are not historical facts. These statements reflect management's current estimates, beliefs, intentions, and expectations; they are not guarantees of future performance. Microbix cautions that all forward-looking information is inherently uncertain and actual performance may be affected by many material factors, some of which are beyond its control. Accordingly, actual future events, conditions and results may differ materially from the estimates, beliefs, intentions, and expectations expressed or implied in the forward-looking information. All statements are made as of the date of this news release and represent Microbix's judgement as of the date of this new release, and it is under no obligation to update or alter any forward-looking information. Please visit or for recent Microbix news and filings. For further information, please contact Microbix at: Copyright © 2025 Microbix Biosystems Inc. Microbix®, DxTM™, Kinlytic®, and QAPs™ are trademarks of Microbix Biosystems Inc. FLOQ® and FLOQSwab® are trademarks of Copan Italia S.p.A. Other companies' names and products are protected by their respective trademarks.

This Experimental Weight Loss Drug Works Without the Nausea or Vomiting
This Experimental Weight Loss Drug Works Without the Nausea or Vomiting

Gizmodo

time20 hours ago

  • Gizmodo

This Experimental Weight Loss Drug Works Without the Nausea or Vomiting

What if you could lose weight with a drug that won't make you lose your lunch at the same time? New research shows it might be possible. Scientists at the University of Pennsylvania, the University of Kentucky, and other institutions say they've found a potentially novel way to suppress people's appetite and treat obesity—without causing the nausea or vomiting commonly experienced with semaglutide (the active ingredient in Ozempic and Wegovy). In early animal experiments, the team's experimental drug appears to be working as intended. Semaglutide and similar drugs mimic the natural GLP-1 hormone, which is important to regulating our insulin production and hunger. As effective as these medications are at helping people lose weight, they have their tradeoffs—most notably a high chance of gastrointestinal side effects. So there's clearly still a need for improved obesity treatments, according to lead study author Caroline Geisler, an assistant professor at UKY's College of Pharmacy. This Simple Strategy Could Curb One of Semaglutide's Worst Side Effects Geisler and her team have been exploring one particular strategy for treating obesity, involving a protein called octadecaneuropeptide, or ODN. ODN is produced by the brain's glia, specialized cells that support neurons. But glia aren't just the brain's support troops, and ODN seems to be important to controlling our sense of hunger. 'Now we know that [glia] play a large role in sensing and communicating the status of the body, and we hope that by targeting a glial signaling molecule, we can engage many energy-regulating pathways in the brain and avoid the side effects of nausea and vomiting,' Geisler told Gizmodo. The researchers first tested their hypothesis by delivering ODN directly to the hindbrain of rats. Once treated, the rats lost weight and improved their blood sugar control. And when they blocked ODN signaling in rats, the animals exhibited a weaker response to GLP-1 treatment (suggesting its effects are at least partly tied to ODN). Finally, they indirectly dosed mice, rats, and shrews with an experimental drug derived from ODN, called TDN. In mice, TDN improved blood sugar control; in rats, it caused weight loss without nausea or vomiting; and in shrews (animals commonly used to test motion sickness and vomiting), the drug triggered no puking at all. The drug also appeared to not have any noticeable effects on the animals' heart rate, movement, and temperature. 'This paper shows for the first time that giving a smaller version of ODN in the periphery is still effective to improve body weight and metabolic control without side effects,' Geisler said. The team's findings, published Wednesday in Science Translational Medicine, are only a proof of concept for now. There remain many questions about exactly how ODN works in the brain to tamp down our appetite and control blood sugar. It's also possible that ODN-based drugs can be further optimized for medical use, though TDN seemed to produce steady weight loss in animals for at least over a week without waning. Still, the researchers are hopeful this potential new drug class can match or even surpass the effectiveness of today's GLP-1 therapies while being less of a hassle to take. And they're now planning to develop such drugs for testing in people. 'We have an optimistic timeline that we could be ready to start clinical trials within 2 years,' Geisler said. The Best Obesity Drugs Aren't Even Here Yet The study researchers are hardly the only ones working to introduce the next generation of improved obesity and diabetes treatments. But it's likely plenty of people would sign up for a safe weight loss drug that comes without the need for a barf bag.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store